## **Subject Index**

A drenergic receptors agonists, hibernation, 272 agonists, hypothermia, 275 diversity, 253 opioid interactions, 362 Affinity labeling of opioid receptors, 347 Alzheimer's disease, role of glutamate receptors, 475

AMPA receptor calcium release, 457 dopamine release, 457 Antipsychotic drugs and D<sub>2</sub> and D<sub>3</sub> receptors, 279

Aspartame effects on receptors, 311

B ungarotoxin complex with fragment, 222

C alcium channels, 448, 457 fluxes, 421 regulation, 446 Cholinergic receptors binding sites, 133 muscle receptors, 101 pathways, 169 rapid kinetics, 23 subunit sites, 139 Chronic effects

neurodegenerative disorders, 501 nicotine, 159, 239 nicotine, dopamine interaction, 245 opiate receptors, 353 Cycloserine, 481

D opaminergic receptors neurotensin interactions, 368, 377 nicotinic interactions, 238, 245 regulation, 293, 298 subtypes, 278 Down-regulation of M<sub>2</sub> receptors, 183

E pilepsy, role of EAA receptors, 492 Excitatory amino acids receptors, 418 role in epilepsy, 492 role in ischemia, 492 Expression

Expression adrenergic receptors, 257 G-proteins, 181 GABA<sub>A</sub> receptor, 508, 518 glutamate receptors, 469 muscarinic receptors, 180 nicotinic receptors, 163 second messenger regulation, 164

G -protein coupling, muscarinic receptor, 215

receptor, distribution, 506, 517 receptor, function, 516 receptor, structure, 516 receptor, subunits, 506 release, and glutamate receptor, 439 Glutamate

aspartame effects, 311
release, nicotine effect, 241
Glutamate receptor
and brain plasticity, 460
effect on calcium channels, 457
epilepsy, 497
functional role, 495
memory function, 475
modulation of GABA release, 439

H istamine receptor subtypes, 314

I schemia, role of EAA receptors, 492

K inetics, rapid chemical methods, 23

L igand-gated ion channel agonists, 40 antagonists, 42 pharmacophore, 44

M ecamylamine, effects, 245
Memory, and glutamate receptors, 475
Metabotropic receptors
role in brain plasticity, 460
role in epilepsy, 492
role in ischemia, 492
subtypes, 418
Monoamines, metabolism, 294
Muscarinic receptors
autoregulation, 194
nitrosylation, 215
regulation, 180

N erve growth factor, 161 Neuropeptides effects on CCK receptor, 410 receptor distribution, 390 Neurotensin

concentrations, 275, 383

dopamine interactions, 368, 377 expression, D2, D3 effects, 284

Nicotinic receptors

block, consequences, 79

effect on transmitter release, 241

effects on other receptors, 240

effects on presynaptic interactions, 238

fragment, 117

functional characterization, 48, 75

heterogeneity, 241

ion permeability, 62

modulation of activity, 55, 60

neuroanatomical mapping, 73

neuronal, subtypes, 100 physiological functions, 63

recognition sites, 120, 126

regulation, 76

subtypes, 56

subunit mRNA, 53 NMDA receptors

calcium release, 457

dopamine release, 457

polyamine modulation, 430

schizophrenia, 487

pioid receptors adrenergic interactions, 362

antagonists, 17

changes, 353

cloning, 332

ligands, 13, 14, 19

purification, 324

regulation, 353

subtypes, 339

eptides

bungarotoxin, 103, 105, 145, 147

design for ligand, 12

G-proteins, 120 mecamylamine, 122, 129

Phosphorylation of nicotinic receptors, 197

Polyamines

effects on immobility, 437

modulating NMDA receptors, 430

Postsynaptic cholinergic pathways, 173

Presynaptic nicotine effects, 238

Protein kinase, adrenergic effects, 263

K eceptor subtypes

catecholamine, 8

GABA, 506

histamine receptor, 514

metabotropic receptors, 418

muscarinic receptors, 186

neuronal nicotinic, 100, 128, 153

nicotinic, 56

nicotinic, antibodies, 130

nicotinic, functional relevance, 156

nicotinic, homologous sequences, 142 nicotinic, ion permeability, 121

nicotinic, regulation, 158

opiate receptor, 339

opioid, 8, 339

peptide, 8

Receptors cholecystokinin, 410

evolution, 45

excitatory amino acid, 418

interactions, 238, 365

molecular organization, 7

neuropeptide, 390

NMDA, 430

overview, 1

sensitivity, 1

subunits, 1

superfamilies, 42

tachykinin, 405

viral, aglyco pathology, 413

Regulation

adrenergic receptor expression, 257

adrenergic receptors, 261, 266

by combined agonist and antagonist, 218

by selective agonists, 356

metabotropic receptors, 467

muscarinic gene expression, 181

nicotinic, second messenger, 164

nicotinic subtypes, 158, 162

D<sub>2</sub> receptor, 368

D<sub>3</sub> receptor, 285

δ receptor, 354

μ receptor, 353

Release of acetylcholine, muscarinic, 194

Reticular activating system, 175

Schizophrenia

and D<sub>2</sub> receptor interactions, 373 and NMDA receptor, 487

neurotensin function, 385

Second messenger regulation of nicotinic

receptors, 164

Serotonergic regulation, 293, 301

Sodium channels, 1

Specificity

neuronal acetylcholine receptors, 103

μ-receptor ligands, 342

δ-receptor ligands, 343

κ-receptor ligands, 346
receptor recognition, 41
Substance P binding, 405
Subunit
composition of acetylcholine
receptors, 134
identity of structure, 155
muscle acetylcholine receptor, 136
nicotinic, peptide fragment, 222
of GABA<sub>A</sub> receptor, 506
synthetic sequence, 135

T achykinin receptor, 405 Transduction systems, 1 Tyrosine kinase, phosphorylation of ACh receptor, 197

Voltage-dependent ion channels calcium channels, 457 recognition sites, 120



## **Index of Contributors**

Abood, L. G., 1–6, 120–132 Adrian, T. E., 410–412 Agnati, L. F., 365–376 Albuquerque, E. X., 48–72 Alkondon, M., 48–72 Anand, R., 100–116 Aronstam, R. S., 215–217 Arrang, J.-M., 314–323 Arvidsson, U., 390–404

Balla, A., 84–99 Basus, V. J., 222–237 Behm, F. M., 218–221 Bissett, G., 275–277 Bogoch, E. S., 413–417 Bogoch, S., 413–417 Borsodi, A., 339–352 Boyd, N. D., 405–409

Carvalho, A. L., 439–456
Carvalho, A. P., 439–456, 457–459
Carvalho, C. M., 457–459
Castro, N. G., 48–72
Cenajek-Musiał, D., 437–438
Chakrabarti, S., 390–404
Chang, S. L., 353–361
Cheng, J., 332–338
Chiappinelli, V., 133–152
Clarke, P. B. S., 73–83
Cockcroft, V., 40–47
Conti-Fine, B. M., 133–152
Cooley, H. G., 215–217
Cotman, C. W., 460–474

Dado, R., 390–404 Dennison, R. L., 215–217 Descarries, L., 293–310 Dewar, K. M., 293–310 Diaz, J., 278–292 Dimitriadou, V., 278–292 Drutel, G., 314–323 Duarte, C. B., 439–456, 457–459 Dumas, J. J., 405–409

Elde, R., 390-404

**F**erraro, L., 365–376 Ferreira, I. L., 439–456 Fonnum, F., 475–486 Fuxe, K., 365–376 Gao, B., 261–271 Garbarg, M., 314–323 Ge, L.-J., 353–361 Gentile, L. N., 117–119, 222–237 Gerzanich, V., 100–116 Gold, M. S., 410–412 Goldman, P. S., 180–185 Griffon, N., 278–292 Gross, R., 377–389 Guiney, W. B., 410–412

Habecker, B. A., 180–185 Harrison, L. M., 353–361 Hashim, A., 275–277 Hawrot, E., 117–119, 222–237 Hedlung, P., 365–376 Hess, G. P., 23–39 Hökfelt, T., 390–404 Hruby, V. J., 7–22 Huganir, R. L., 197–214

Ishac, E. J. N., 261-271

Jaiswal, N., 194–196 Javitt, D. C., 487–491 Jiang, L., 261–271 Jurányi, Zs., 84–99

Kage, R., 405-409 Kastin, A. J., 353-361 Kende, A. S., 120-132 Kesslak, J. P., 460-474 Kilts, C. D., 377-389 Kimura, H., 516-527 Krause, J. E., 405-409 Kunos, G., 261-271 Kuriyama, K., 516-527

Lajtha, A., 84-99, 238-244, 311-313 Lambert, P. D., 377-389 Lammers, C. H., 278-292 Lane, J. D., 218-221 Law, P. Y., 390-404 Lee, J.-H., 390-404 Leeman, S. E., 405-409 Lerner-Marmarosh, N., 120-132 Levesque, D., 278-292 Levin, E. D., 218-221, 245-252 Li, Y., 100-116 Li, X.-M., 365-376 Lindstrom, J., 100-116 Loh. H. H., 390-404 London, E. D., 430-436 Lukas, R. J., 153-168 Lunt, G., 40-47

Maelicke, A., 48–72, 133–152 Malva, J. O., 457–459 Martin, D. C., 215–217 Martres, M.-P., 278–292 McLane, K. E., 133–152 Meldrum, B. S., 492–506 Mesulam, M., 169–179 Migeon, J. C., 180–185 Mike, A., 84–99 Miller, S., 460–474 Mukhin, A., 430–436 Myhrer, T., 475–486

Naftchi, N. E., 272–274, 275–277 Nakano, A., 390–404 Nakayasu, H., 516–527 Nathanson, N. M., 180–185 Nemeroff, C. B., 377–389 Niu, L., 23–39

O'Connor, W. T., 365–376 Øksengård, A. R., 475–486 Ortells, M., 40–47

Pan, Y-X., 332–338 Park, D. H., 362–364 Pasternak, G. W., 332–338 Paulsen, R. E., 475–486 Peng, X., 100–116 Pereira, E. F. R., 48–72 Pilon, C., 278–292 Porreca, F., 7–22

**Q**u, Z., 197–214

Radja, F., 293–310 Reader, T. A., 293–310 Récasens, M., 418–429 Reilly, M. A., 311–313 Reinhardt, S., 48–72 Reinhardt-Maelicke, S., 133–152 Rhee, H. M., 362–364 Riedl, M., 390–404 Ripka, G. V., 218–221 Robinson, D. C., 410–412 Romano, C., 460–474 Rose, J. E., 218–221, 245–252 Ruat, M., 314-323 Rudnicki, M., 410-412

Sastry, B. V. R., 194–196 Schröder, H., 48–72 Schwartz, J.-C., 278–292, 314–323 Sershen, H., 84–99, 238–244, 275–277 Shi, Q.-L., 222–237 Silberman, S. C., 405–409 Simon, E. J., 324–331 Sokoloff, P., 278–292 Stein, R. M., 218–221 Strosberg, A. D., 253–260 Swope, S. L., 197–214 Szczawińska, K., 437–438

Tanganelli, S., 365–376 Tayeb, O. S., 194–196 Tito, J. M., 410–412 Toth, E., 238–244 Toth, G., 339–352 Traiffort, E., 314–323

Ungerstedt, U., 365–376

Vignes, M., 418–429 Vizi, E. S., 84–99, 238–244 Vulchanova, L., 390–404

Wang, D. X., 120–132 Wang, F., 100–116 Wangen, K., 475–486 Wessendorf, M., 390–404 Westman, E. C., 218–221 Wieboldt, R., 23–39 Windisch, K., 84–99 Wisden, W., 506–515 Wolfe, B. B., 186–193

**Y**amamura, H. I., 7–22 Yasuda, R. P., 186–193

Zadina, J. E., 353–361 Zhang, X., 390–404 Zukin, S. R., 487–491 Zylberman, I., 487–491

